Prostate Adenocarcinoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
Customized TULSA-PRO Ablation Registry
Recruiting
  • Prostate Cancer
  • +2 more
  • TULSA Procedure
  • West Hills, California
  • +4 more
2022-04-06
Apr 6, 2022
U
68Ga-PSMA-11 PET in Patients With Prostate Cancer
Recruiting
  • Prostate Cancer
  • Prostate Adenocarcinoma
  • Aurora, Colorado
  • +1 more
2022-04-05
Apr 5, 2022
U
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-04-04
Apr 4, 2022
E
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Recruiting
  • Metastatic Prostate Cancer
  • Prostate Adenocarcinoma
  • Tucson, Arizona
  • +232 more
2022-03-28
Mar 28, 2022
A
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Recruiting
  • Prostate Adenocarcinoma
  • Niraparib Pill
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
2022-03-29
Mar 29, 2022
W
Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer
Recruiting
  • Prostate Adenocarcinoma
  • +3 more
  • Interview
  • Questionnaire Administration
  • Phoenix, Arizona
  • +324 more
2022-03-29
Mar 29, 2022
N
Trial of NanoPac Focal Therapy for Prostate Cancer - 2021
Terminated
Has Results
  • Prostate Cancer
  • +6 more
  • NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
  • Tampa, Florida
  • +3 more
2022-03-02
Mar 2, 2022
J
Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)
Active, not recruiting
  • Prostate Cancer
  • +3 more
  • Stereotactic Body Radiation Therapy with Integrated Boost
  • Birmingham, Alabama
    Hazelrig-Salter Radiation Oncology Center
2022-03-25
Mar 25, 2022
R
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
Recruiting
  • Prostate Adenocarcinoma
  • +9 more
  • Angiogram
  • +3 more
  • San Francisco, California
    University of California San Francisco
2022-03-24
Mar 24, 2022
U
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
Recruiting
  • Castration-Sensitive Prostate Carcinoma
  • +7 more
  • Antiandrogen Therapy
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-22
Mar 22, 2022
U
Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis
Not yet recruiting
  • Prostate Adenocarcinoma
  • Salt Lake City, Utah
    Huntsman Cancer Institute at University of Utah
2022-03-16
Mar 16, 2022
C
Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma
Recruiting
  • Prostate Adenocarcinoma
  • Clermont-Ferrand, France
  • +5 more
2022-03-14
Mar 14, 2022
P
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
Recruiting
  • Prostate Cancer
  • Prostate Adenocarcinoma
  • Radical Prostatectomy
  • TULSA Procedure
  • Tarzana, California
  • +6 more
2022-03-11
Mar 11, 2022
U
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
Not yet recruiting
  • Prostate Cancer
  • +3 more
  • Abiraterone Oral Tablet
  • +3 more
  • (no location specified)
2022-03-02
Mar 2, 2022
U
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Active, not recruiting
  • Prostate Cancer
  • +3 more
  • Ann Arbor, Michigan
    University of Michigan
2022-03-10
Mar 10, 2022
E
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging
Recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • 3-Dimensional Conformal Radiation Therapy
  • +11 more
  • Duarte, California
  • +35 more
2022-03-09
Mar 9, 2022
U
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
Recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • +6 more
  • Computed Tomography
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-07
Mar 7, 2022
U
Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma
Active, not recruiting
  • Prostate Adenocarcinoma
  • F-18 fluciclovine-PET/CT scan
  • Tucson, Arizona
    University of Arizona
2022-03-07
Mar 7, 2022
A
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Active, not recruiting
  • Prostate Adenocarcinoma
  • Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
  • +2 more
  • Palo Alto, California
    Stanford University, School of Medicine
2022-03-02
Mar 2, 2022
L
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
Recruiting
  • Prostate Adenocarcinoma
  • +2 more
  • San Francisco, California
  • +1 more
2022-02-14
Feb 14, 2022
S
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Not yet recruiting
  • Prostate Adenocarcinoma
  • +2 more
  • radium-223
  • Bipolar Androgen Therapy (BAT)
  • Baltimore, Maryland
  • +1 more
2022-03-02
Mar 2, 2022
S
Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer
Suspended
  • Prostate Adenocarcinoma
  • Obesity, Morbid
  • Bead Block 300-500 um
  • +2 more
  • Baltimore, Maryland
    Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive C
2022-02-14
Feb 14, 2022
M
Fluorescent Imaging of Nerves With Illuminare-1 During Surgery
Recruiting
  • Prostate Adenocarcinoma
  • Basking Ridge, New Jersey
  • +5 more
2022-02-28
Feb 28, 2022
N
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
Active, not recruiting
  • Male Breast Carcinoma
  • +7 more
  • Stereotactic Body Radiation Therapy (SBRT)
  • Birmingham, Alabama
  • +77 more
2022-02-28
Feb 28, 2022
M
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
Active, not recruiting
  • Prostate Adenocarcinoma
  • +5 more
  • Daratumumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-25
Feb 25, 2022